Indication of Liver Transplantation for Hepatocellular Carcinoma Should Be Reconsidered in Case of Microvascular Invasion and Multilocular Tumor Occurrence

• Main Authors: Jan-Paul Gundlach, Stephan Schmidt, Alexander Bernsmeier, Rainer Günther, Victor Kataev, Jens Trentmann, Jost Philipp Schäfer, Christoph Röcken, Thomas Becker, Felix Braun
• Format: Article
• Language: English
• Published: MDPI AG 2021-03-01
• Series: Journal of Clinical Medicine
• Subjects: HCC; hepatocellular carcinoma; liver transplantation; microvascular invasion; multilocular; downstaging
• Online Access: https://www.mdpi.com/2077-0383/10/6/1155

Liver transplantation (LT) is routinely performed for hepatocellular carcinoma (HCC) in cirrhosis without major vascular invasion. Although the adverse influence of microvascular invasion is recognized, its occurrence does not contraindicate LT. We retrospectively analyzed in our LT cohort the significance of microvascular invasion on survival and demonstrate bridging procedures. At our hospital, 346 patients were diagnosed with HCC, 171 patients were evaluated for LT, and 153 were listed at Eurotransplant during a period of 11 years. Among these, 112 patients received LT and were included in this study. Overall survival after 1, 3 and 5 years was 86.3%, 73.9%, and 67.9%, respectively. Microvascular invasion led to significantly reduced overall (<i>p </i>= 0.030) and disease-free survival (<i>p </i>= 0.002). Five-year disease-free survival with microvascular invasion was 10.5%. Multilocular tumor occurrence with simultaneous microvascular invasion revealed the worst prognosis. In our LT cohort, predominant bridging treatment was transarterial chemoembolization (TACE) and the number of TACE significantly correlated with poorer overall survival after LT (<i>p </i>= 0.028), which was confirmed in multiple Cox regression analysis for overall and disease-free survival (<i>p </i>= 0.015 and <i>p </i>= 0.011). Microvascular tumor invasion is significantly associated with reduced prognosis after LT, which is aggravated by simultaneous occurrence of multiple lesions. Therefore, indication strategies for LT should be reconsidered.